Pharmacist Interventions in Rural Elderly Warfarin Patients
Primary Purpose
Atrial Fibrillation, Thrombosis, Cardiac Failure
Status
Completed
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
anticoagulation care
Sponsored by
About this trial
This is an interventional health services research trial for Atrial Fibrillation focused on measuring pharmacist interventions, warfarin, elderly rural patients
Eligibility Criteria
Inclusion Criteria:
- Age ≥65 years
- Living site of participant outside the city eg. rural site
- Expected duration of warfarin therapy at least 6 months from the inclusion in the study and 3 months before
Exclusion Criteria:
- Hospitalization
- Vegetarianism
- Patients not able to provide an informed consent
- The use of drug that has an X level of clinical significance of interaction with warfarin according to Lexicomp interact base
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
No Intervention
Arm Label
Intervention
Control
Arm Description
Specific pharmacist-led anticoagulation care
The control group will receive usual care; no interventions will be administered.
Outcomes
Primary Outcome Measures
Time in therapeutic range (TTR)
Time in therapeutic range by Rosendaal method (percentage of time in therapeutic range)
Secondary Outcome Measures
Adverse drug reactions
To measure the difference in number and types of adverse drug reactions between the intervention and the control group
Time to adverse drug reaction
To measure the difference in time to adverse drug reactions between the intervention and the control group
International randomised ratio
To measure the difference in patterns of the International randomised ratio between the intervention and the control group
Adherence
To measure the difference in adherence between the intervention and the control group
Quality of life
To measure the difference of the quality of life in the intervention and the control group at the beginning and the end of the study (validated Croatian version of DUKE - Duke anticoagulation satisfaction scale questionaire)
Incidence and influence of clinically significant drug interactions
To measure the incidence of clinically significant drug interactions (defined by the Lexicomp-interact base as degree C and D of clinical significance) and influence of drug interactions on the effectiveness and safety of treatment between the intervention and the control group
Dietary intake of vitamin K
Changes of dietary intake of vitamin K
Acceptance of pharmacist's intervention by the general practitioners
To measure the rate of acceptance of pharmacist's interventions by the general practitioners
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT03212898
Brief Title
Pharmacist Interventions in Rural Elderly Warfarin Patients
Official Title
The Influence of Pharmacist Interventions on the Effectiveness of Warfarin Treatment in Elderly Patients From Rural Areas
Study Type
Interventional
2. Study Status
Record Verification Date
July 2017
Overall Recruitment Status
Completed
Study Start Date
May 2015 (Actual)
Primary Completion Date
January 2017 (Actual)
Study Completion Date
January 2017 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Slaven Falamić
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
The primary study goal is to explore the influence of pharmacist interventions on the effectiveness of warfarin treatment in a specific subpopulation.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Atrial Fibrillation, Thrombosis, Cardiac Failure, Hemorrhage
Keywords
pharmacist interventions, warfarin, elderly rural patients
7. Study Design
Primary Purpose
Health Services Research
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare Provider
Allocation
Randomized
Enrollment
131 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Intervention
Arm Type
Experimental
Arm Description
Specific pharmacist-led anticoagulation care
Arm Title
Control
Arm Type
No Intervention
Arm Description
The control group will receive usual care; no interventions will be administered.
Intervention Type
Other
Intervention Name(s)
anticoagulation care
Intervention Description
Patients in the intervention group will: 1) have a repeated pharmacist-led education on all aspects of warfarin treatment; 2) receive enhanced medication instructions and a care and follow up plan; 3) receive a pill box 4) be refered to the GP with proposal for dose change when outside the therapeutic range or therapy modification to avoid drug interactions with warfarin
Primary Outcome Measure Information:
Title
Time in therapeutic range (TTR)
Description
Time in therapeutic range by Rosendaal method (percentage of time in therapeutic range)
Time Frame
6 months
Secondary Outcome Measure Information:
Title
Adverse drug reactions
Description
To measure the difference in number and types of adverse drug reactions between the intervention and the control group
Time Frame
6 months
Title
Time to adverse drug reaction
Description
To measure the difference in time to adverse drug reactions between the intervention and the control group
Time Frame
6 months
Title
International randomised ratio
Description
To measure the difference in patterns of the International randomised ratio between the intervention and the control group
Time Frame
6 months
Title
Adherence
Description
To measure the difference in adherence between the intervention and the control group
Time Frame
6 months
Title
Quality of life
Description
To measure the difference of the quality of life in the intervention and the control group at the beginning and the end of the study (validated Croatian version of DUKE - Duke anticoagulation satisfaction scale questionaire)
Time Frame
6 months
Title
Incidence and influence of clinically significant drug interactions
Description
To measure the incidence of clinically significant drug interactions (defined by the Lexicomp-interact base as degree C and D of clinical significance) and influence of drug interactions on the effectiveness and safety of treatment between the intervention and the control group
Time Frame
6 months
Title
Dietary intake of vitamin K
Description
Changes of dietary intake of vitamin K
Time Frame
6 months
Title
Acceptance of pharmacist's intervention by the general practitioners
Description
To measure the rate of acceptance of pharmacist's interventions by the general practitioners
Time Frame
6 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Age ≥65 years
Living site of participant outside the city eg. rural site
Expected duration of warfarin therapy at least 6 months from the inclusion in the study and 3 months before
Exclusion Criteria:
Hospitalization
Vegetarianism
Patients not able to provide an informed consent
The use of drug that has an X level of clinical significance of interaction with warfarin according to Lexicomp interact base
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Slaven Falamić, MPharm
Organizational Affiliation
Pharmacy Branka Marušić
Official's Role
Principal Investigator
12. IPD Sharing Statement
Citations:
PubMed Identifier
34754004
Citation
Falamic S, Lucijanic M, Ortner-Hadziabdic M, Marusic S, Bacic-Vrca V. Pharmacists' interventions improve health-related quality of life of rural older person on warfarin: a randomized controlled trial. Sci Rep. 2021 Nov 9;11(1):21897. doi: 10.1038/s41598-021-01394-0.
Results Reference
derived
Learn more about this trial
Pharmacist Interventions in Rural Elderly Warfarin Patients
We'll reach out to this number within 24 hrs